Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.

Patients with familial hypercholesterolemia (FH) have had a life-long sustained elevation of low-density lipoprotein (LDL) cholesterol levels. Consequently, there is a need to maximally lower their elevated levels, and this usually requires lowering LDL levels more than 50%. Because no single hypolipidemic drug will consistently produce such degrees of lowering, combination drug therapy with two or even three agents is required to produce the desired degree of cholesterol lowering. A prospective trial was designed to determine if combination therapy using three hypolipidemic agents could effectively lower LDL levels in 17 severely affected FH subjects. Colestipol hydrochloride (10 g b.i.d.), probucol (500 mg b.i.d.), and lovastatin (20 or 40 mg b.i.d.) were given to each patient, in varying combinations, over a 25-month period. Lovastatin (40 mg/day) uniformly lowered LDL levels 36%. Probucol lowered LDL only 14% and in a variable manner. The combination of lovastatin and probucol lowered LDL no better than lovastatin alone. Lovastatin plus colestipol lowered LDL 52%; probucol added as a third agent produced no further lowering. Lovastatin (80 mg/day) plus colestipol lowered LDL 56%. Lovastatin increased high-density lipoprotein (HDL) cholesterol levels 6%, whereas probucol decreased HDL 29%. In all patients there was an effective lowering of LDL levels, ranging from 40% to 70%. Thus, lovastatin plus colestipol is an effective hypolipidemic regimen for producing marked decreases in LDL levels in FH subjects. The addition of probucol as a third hypolipidemic agent adds little to the therapeutic regimen as measured by lowering of LDL levels.

[1]  S M Grundy,et al.  Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Clifton,et al.  Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolemia , 1990, The Medical journal of Australia.

[3]  S. Grundy.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. , 1988, The New England journal of medicine.

[4]  R. Lees,et al.  Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. , 1987, Annals of internal medicine.

[5]  M. Malloy,et al.  Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. , 1987, Annals of internal medicine.

[6]  T. Carew,et al.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Ooshima,et al.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[9]  J. Witztum.  Intensive drug therapy of hypercholesterolemia. , 1987, American heart journal.

[10]  T. Funahashi,et al.  Effects of probucol on xanthomata regression in familial hypercholesterolemia. , 1986, The American journal of cardiology.

[11]  K. Bailey,et al.  Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. , 1986, The American journal of cardiology.

[12]  A. Chait,et al.  Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. , 1986, The Journal of clinical investigation.

[13]  S. Young,et al.  Probucol inhibits oxidative modification of low density lipoprotein. , 1986, The Journal of clinical investigation.

[14]  S. Grundy,et al.  Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. , 1985, Journal of lipid research.

[15]  S. Grundy,et al.  Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. , 1985, Annals of internal medicine.

[16]  J. Albers,et al.  Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. , 1985, Metabolism: clinical and experimental.

[17]  M. Virkkunen.  Lipid Research Clinics Coronary Primary Prevention Trial results. , 1985, JAMA.

[18]  D. Illingworth,et al.  Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. , 1984, The Journal of clinical investigation.

[19]  T. Carew,et al.  A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. , 1984, Journal of lipid research.

[20]  D R Illingworth,et al.  Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. , 1984, Annals of internal medicine.

[21]  J L Witztum,et al.  Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Krehbiel,et al.  Probucol with colestipol in the treatment of hypercholesterolemia. , 1984, Annals of internal medicine.

[23]  Y. Matsuzawa,et al.  Effects of probucol on homozygous cases of familial hypercholesterolemia. , 1983, Atherosclerosis.

[24]  H. Mabuchi,et al.  Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. , 1983, The New England journal of medicine.

[25]  B. Joffe,et al.  Treatment of homozygous familial hypercholesterolaemia with probucol. , 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[26]  C. Glueck.  Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. , 1982, Annals of internal medicine.

[27]  Y. Chao,et al.  Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. , 1982, The Journal of clinical investigation.

[28]  D. Steinberg,et al.  Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Kostis,et al.  Familial type II hyperlipoproteinemia with coronary heart disease: effect of diet-colestipol-nicotinic acid treatment. , 1981, Chest.

[30]  D. Illingworth,et al.  COLESTIPOL PLUS NICOTINIC ACID IN TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA , 1981, The Lancet.

[31]  D. Bilheimer,et al.  Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M J Malloy,et al.  Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. , 1981, The New England journal of medicine.

[33]  T. B. Clarkson,et al.  A study of atherosclerosis regression in Macaca mulatta: III. Chemical changes in arteries from animals with atherosclerosis induced for 19 months and regressed for 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. , 1980, The American journal of pathology.

[34]  R Monaghan,et al.  Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. G. Morgan,et al.  Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. , 1980, The New England journal of medicine.

[36]  T. Miettinen.  Effects of neomycin alone and in combination with cholestyramine on serum cholesterol and fecal steroids in hypercholesterolemic subjects. , 1979, The Journal of clinical investigation.

[37]  C. Packard,et al.  Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. , 1979, The Journal of clinical investigation.

[38]  G. Schonfeld,et al.  Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins. , 1979, Metabolism: clinical and experimental.

[39]  G. Schonfeld,et al.  The effects of colestipol on the metabolism of very-low-density lipoproteins in man. , 1976, The Journal of laboratory and clinical medicine.

[40]  J. Verter,et al.  Coronary Artery Disease in 116 Kindred with Familial Type II Hyperlipoproteinemia , 1974, Circulation.

[41]  A. George.  The metabolic basis of inherited disease , 1961 .

[42]  J. Sasaki,et al.  Alterations in lipoprotein with discontinuation of probucol , 1987 .

[43]  Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II. , 1986, JAMA.

[44]  S. Young,et al.  Cholestyramine-induced changes in low density lipoprotein composition and metabolism. I. Studies in the guinea pig. , 1985, Journal of lipid research.

[45]  The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. , 1984, JAMA.

[46]  G. Schonfeld,et al.  Probucol further lowers the serum cholesterol of colestipol-treated patients with hypercholesterolemia. , 1982, Artery.

[47]  H. G. Morgan,et al.  Combined drug therapy for familial hypercholesterolemia. , 1980, Artery.